Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
3.44
Dollar change
+0.20
Percentage change
6.17
%
Index- P/E- EPS (ttm)-2.72 Insider Own23.72% Shs Outstand67.19M Perf Week4.88%
Market Cap245.41M Forward P/E- EPS next Y-0.45 Insider Trans14.10% Shs Float51.26M Perf Month42.15%
Income-19.57M PEG- EPS next Q-0.09 Inst Own45.27% Short Float0.56% Perf Quarter196.55%
Sales0.00M P/S- EPS this Y74.70% Inst Trans- Short Ratio0.53 Perf Half Y143.97%
Book/sh-0.07 P/B- EPS next Y49.82% ROA-175.81% Short Interest0.29M Perf Year173.02%
Cash/sh0.05 P/C75.74 EPS next 5Y- ROE-270.10% 52W Range1.12 - 3.82 Perf YTD170.87%
Dividend Est.- P/FCF- EPS past 5Y-23.31% ROI- 52W High-9.95% Beta1.16
Dividend TTM- Quick Ratio0.74 Sales past 5Y49.79% Gross Margin- 52W Low207.14% ATR (14)0.36
Dividend Ex-Date- Current Ratio0.74 EPS Y/Y TTM31.38% Oper. Margin- RSI (14)72.06 Volatility13.70% 13.33%
Employees8 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q24.38% Payout- Rel Volume0.63 Prev Close3.24
Sales Surprise- EPS Surprise-35.42% Sales Q/Q-100.00% EarningsNov 14 BMO Avg Volume542.29K Price3.44
SMA2029.15% SMA5043.46% SMA20089.82% Trades Volume342,738 Change6.17%
Nov-14-24 08:37AM
Oct-23-24 06:31AM
Oct-22-24 09:07PM
Oct-21-24 09:05AM
Oct-18-24 01:01AM
05:57PM Loading…
Oct-11-24 05:57PM
01:02PM
Oct-10-24 08:59AM
Oct-09-24 09:18AM
Aug-14-24 04:25PM
Aug-07-24 08:00AM
Jun-17-24 08:05AM
Jun-05-24 08:05AM
May-20-24 08:01AM
May-19-24 08:09AM
06:52AM Loading…
May-16-24 06:52AM
May-15-24 08:00PM
08:45AM
May-09-24 08:00AM
Apr-18-24 04:30PM
Apr-03-24 08:05AM
Apr-02-24 10:25AM
Mar-28-24 09:06PM
Mar-27-24 10:53PM
04:15PM
Mar-07-24 08:30AM
Feb-28-24 04:05PM
Feb-15-24 09:55AM
Feb-07-24 07:55AM
Jan-29-24 09:05AM
12:00PM Loading…
Jan-22-24 12:00PM
Jan-16-24 04:05PM
Dec-19-23 08:30AM
Dec-04-23 08:35AM
Nov-14-23 04:30PM
Nov-07-23 09:28AM
08:00AM
Oct-16-23 07:00AM
Oct-04-23 08:30AM
Sep-20-23 08:30AM
Aug-24-23 08:30AM
Aug-22-23 08:05AM
Aug-21-23 08:30AM
Aug-17-23 08:30AM
Aug-15-23 11:47PM
Aug-14-23 04:20PM
Aug-07-23 08:05AM
Jul-17-23 04:05PM
Jun-29-23 09:29AM
Jun-22-23 08:05AM
Jun-21-23 08:05AM
May-30-23 08:05AM
May-24-23 12:04PM
May-17-23 06:11AM
May-16-23 07:45AM
May-15-23 08:30AM
May-09-23 07:15AM
May-08-23 08:05AM
May-04-23 08:05AM
May-02-23 03:30PM
Apr-26-23 08:00AM
Apr-24-23 09:00AM
Apr-21-23 08:30AM
Apr-07-23 10:25PM
Mar-31-23 08:22AM
Mar-23-23 05:15PM
Mar-21-23 08:00AM
Mar-16-23 08:30AM
Mar-15-23 08:35AM
Mar-08-23 08:30AM
Feb-15-23 04:05PM
Feb-08-23 01:00PM
Jan-27-23 04:05PM
Jan-25-23 01:00PM
08:35AM
08:05AM
Dec-12-22 04:05PM
Dec-07-22 04:05PM
Nov-22-22 08:00AM
Nov-14-22 05:45PM
Nov-10-22 05:00AM
Nov-08-22 08:00AM
Nov-07-22 08:00AM
Oct-12-22 08:00AM
Sep-21-22 04:05PM
Sep-15-22 08:00AM
Sep-13-22 12:15PM
Sep-08-22 08:30AM
Sep-01-22 04:05PM
Aug-26-22 08:00AM
Aug-23-22 08:00AM
Aug-12-22 04:55PM
Aug-08-22 08:30AM
Jun-13-22 08:00AM
May-16-22 05:00PM
May-10-22 08:05AM
May-09-22 04:05PM
Apr-21-22 04:05PM
Apr-13-22 11:45AM
Apr-06-22 11:37AM
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bellini RobertoDirectorOct 21 '24Buy1.371,460,0002,000,2001,460,000Oct 23 07:53 PM
Kush ArvindDirectorOct 21 '24Buy1.37145,000198,650145,000Oct 23 07:49 PM
Munshi AmitDirectorOct 21 '24Buy1.37365,000500,050365,000Oct 23 07:43 PM